Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy. - Wikidata - awgldk - TriplyDB

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

http://www.wikidata.org/entity/Q39405702

about

Review: Multiple system atrophy: emerging targets for interventional therapies Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity Animal models of multiple system atrophy Environmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.Towards translational therapies for multiple system atrophy α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy Novel therapeutic approaches in multiple system atrophy Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.Sigma-1 receptor: a potential new target for Parkinson's disease?Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy.Antidepressant-like effects of acupuncture involved the ERK signaling pathway in rats Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy.Models of multiple system atrophy Combination therapies: The next logical Step for the treatment of synucleinopathies?Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?Active immunization therapies for Parkinson's disease and multiple system atrophy.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Multiple System Atrophy - State of the Art.Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.The neuropathology of multiple system atrophy and its therapeutic implications.Ketamine Inhibits ATP-Evoked Exocytotic Release of Brain-Derived Neurotrophic Factor from Vesicles in Cultured Rat Astrocytes.Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?Selective serotonin reuptake inhibitors emerge as the therapeutic agent for synucleinopathies.Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy.Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance.

P2860

Q26770919-1FDF8A62-75B8-42D2-AF7E-3C6F6D218043 Q26862840-70AF081C-A836-499E-81C9-59C5B8BCD381 Q27015535-1998BB0E-7DC7-44FD-A131-3F4F795C0F69 Q28304384-D024C56A-400B-4E5B-85F6-1AADC1F17CDC Q28395248-6DBFC571-0D9E-4B73-A2BB-6B06F5C5DC45 Q30578913-6E18BA6A-60E2-4D2A-98F3-E001E93BD4E7 Q30620210-5207EC8E-AEB0-4AB4-9CA2-A1E3E3CE3F05 Q30795299-5AC7732E-FE0B-4298-A674-6DDEEC9BDB69 Q33797532-06F15AF5-A4DD-4305-B64A-17E58D5E45D4 Q33864597-32C7D7B1-B8FE-4E5C-BD16-E4A4F7A114D3 Q34696470-224D4898-13D5-426D-A187-139ABD68533E Q35089378-B104F069-F4C2-4390-81D8-3FF5E7F74186 Q35154720-6069AFE3-6738-4541-8689-7C1EA3540E5F Q35243291-51412784-3462-49E3-99F7-E32254EBBC42 Q35537759-75C1112B-FC78-47D3-ADD5-C461D3CA1723 Q35544737-E3E8A086-CD79-4525-A886-77FAFEF734AB Q36086721-A5F379A0-962D-4320-AD3D-AA41A1B69C73 Q36146843-B0B6A01F-8289-4049-9310-918A64F388D7 Q36341144-4955E333-8C24-42CB-B1C9-7DA3CCB61486 Q36513407-809D7D8C-C69B-4B75-8C1A-5576295C454B Q36563062-7234BF8A-0D34-4BA7-9D0A-EE18647D1FC1 Q36672116-113CBE51-EB9E-4210-87EC-3E4D07601F4C Q36944201-C2190D9B-AA4C-4A01-BD2B-818C0DE17805 Q37565960-1919D865-4F86-4F75-A713-03E7BA78001A Q38475947-38501282-E45D-406C-B502-5C71EF708605 Q38564102-980AF833-C46D-4452-BA76-991629A7DC0E Q38603309-02A9367A-840D-4AB9-98C9-1A746DA422CE Q39220912-53F4424A-F1DC-48C0-AC2C-1F9CD67F98E6 Q41494507-E04A0C41-1C12-4B51-BE2F-669603962C56 Q43247253-45D537D6-2E47-497E-91F6-890ECD89B682 Q45940520-27EA28C5-8715-4E73-AC13-959FC3B25088 Q47616783-A57382B6-EBF0-41D0-A386-C9B29906ECAE Q47677612-5CDECC43-C49E-4A54-B3DF-DB2FD155F006 Q48206256-9B2E8C02-2612-48E9-A29B-85F7359621D8 Q48228354-BD4C6702-0A4B-48B0-8B6D-987F84038F70 Q48395382-719B6CA0-BFEF-4C91-8C13-8584A1852D67 Q52607614-22A1461A-10EA-43A4-8384-209B50618A54

P2860

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

http://www.wikidata.org/entity/Q39405702

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@en

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@nl

type

label

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@en

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@nl

prefLabel

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@en

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@nl

P1433

Q39405702-1C551A66-12BD-41A1-BA0C-A1050A06A1ED

P1476

Q39405702-4585316A-867C-41CB-958F-045F2D6261AA

P2093

Q39405702-26FE7323-98F6-4F57-9245-EE19B318FCDC

Q39405702-2FE8C134-2B30-4344-8DFD-0C5C050FFB4D

Q39405702-78E12E61-540D-444C-973B-343A7B986D47

Q39405702-A5CFAEC9-A3EC-4DB8-BFBE-B6733112984C

Q39405702-B1A4F88B-DB6F-40D4-B2EC-7AC17D18B725

Q39405702-B43BB923-D707-45AC-9B67-05C5A427243B

Q39405702-CA9A42D5-B663-422B-9570-1F71893FB52B

P2860

Q39405702-07C667FB-B860-4795-ADE1-DC9F2F7160C3

Q39405702-097E9AC0-6596-4C53-B22B-5A6E448069B5

Q39405702-0A60EBE1-5EA2-46D8-8C7A-CC33700F2746

Q39405702-0C835A88-5B16-4E36-9EEA-922FF0CAC3F0

Q39405702-0E5790A6-9B54-4A4C-AA30-BF55DD67A793

Q39405702-180A1E38-CD3F-4C99-8B31-32A30B5120A1

Q39405702-1A4827F7-BD88-42A7-AD3F-854CA8899385

Q39405702-218651F9-7CE2-4874-B0C7-B7B3A7E61A0D

Q39405702-2BA73446-AD9D-4FED-84E1-3F30A452C08B

Q39405702-2C9F1D98-F03D-44AE-AB6D-6A7FA67BF7D9

P304

Q39405702-1C561FA2-908B-4D69-AF15-88181520557D

P31

Q39405702-647E8B4F-22DD-4950-88DA-968CCEAEE323

P356

Q39405702-55B4C708-D990-496C-B7BD-CBD8E73ECFB7

P407

Q39405702-8F9652EF-4733-4353-9EC2-189F2924B241

P433

Q39405702-50241D64-BB68-44F1-863D-8D83FBEEB585

P478

Q39405702-2532677C-F541-4D02-9A95-9329B11D9F04

P50

Q39405702-2631CBD5-8C8B-43F7-8EDC-7AABB255AF8D

Q39405702-5453C9A6-84C9-47C0-990A-9F3C15BF8BA1

Q39405702-6BADB72B-CB64-4285-83E4-6D4073463290

P577

Q39405702-EEDBB80E-82D4-4EDB-9DAF-2C1E724B72C2

P698

Q39405702-C07A1B2C-11D1-40F5-A093-78E703261B35

P932

Q39405702-203CA72E-6538-43AF-B92F-799A45F4FC7B

P356

J.EXPNEUROL.2012.01.008

P1433

Experimental Neurology

P1476

Fluoxetine ameliorates behavio ...... el mouse of α-synucleinopathy.

@en

P2093

Anthony Adame

http://www.w3.org/2001/XMLSchema#string

Brian Spencer

http://www.w3.org/2001/XMLSchema#string

Chandra Inglis

http://www.w3.org/2001/XMLSchema#string

Christina Patrick

http://www.w3.org/2001/XMLSchema#string

Juergen Winkler

http://www.w3.org/2001/XMLSchema#string

Michael Mante

http://www.w3.org/2001/XMLSchema#string

Verena May

http://www.w3.org/2001/XMLSchema#string

P2860

The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis

NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy

Neurodegenerative disease and adult neurogenesis

Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade

Serotonin increases ERK1/2 phosphorylation in astrocytes by stimulation of 5-HT2B and 5-HT2C receptors

Neuroregeneration in neurodegenerative disorders.

Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways.

Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.

Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine.

The neurotrophic and neuroprotective effects of psychotropic agents.

P304

405-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPNEUROL.2012.01.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

234

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

Edward Rockenstein

P577

2012-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22281106

http://www.w3.org/2001/XMLSchema#string

P932

3897235

http://www.w3.org/2001/XMLSchema#string